NEP INTERLONG (08329) announced that the group expects a decrease of approximately 80% to 120% in profit attributable to the company's owners for the year ending December 31, 2025, compared to the same period in 2024. The primary reason for the decline is an impairment loss on goodwill recognized by the group in connection with its acquisition of Beijing NEP Zhongxin Pharmaceutical Co., Ltd.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments